No results were found for your search. Please adjust your search term or broaden your search criteria.
Still can't find what you are looking for? We can prepare Custom Research for you.
AZD3293 is a drug used to treat Central Nervous System (CNS) disorders. It is a selective, reversible inhibitor of monoamine oxidase B (MAO-B), an enzyme that breaks down dopamine in the brain. This drug is used to treat Parkinson's disease, a progressive neurological disorder that affects movement, balance, and coordination. It is also used to treat depression, anxiety, and other psychiatric disorders.
AZD3293 is a relatively new drug, and is still in the early stages of development. It is being studied for its potential to treat a variety of CNS disorders, including Alzheimer's disease, Huntington's disease, and schizophrenia.
The AZD3293 market is highly competitive, with many pharmaceutical companies vying for a share of the market. Companies such as AstraZeneca, Pfizer, and Merck are actively researching and developing new drugs to treat CNS disorders. Other companies, such as Novartis, GlaxoSmithKline, and Johnson & Johnson, are also involved in the development of new treatments for CNS disorders. Show Less Read more
